SCHEMBL15345147

SCHEMBL15345147

Cc1ccnc(-c2ccc3c(c2)OCCN3C)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.57
CYP11B2 P19099 1/20 0.57
NOTUM Q6P988 1/20 0.51
CCR1 P32246 1/20 0.46
CCR5 P51681 1/20 0.46
CCR8 P51685 1/20 0.46
GRM5 P41594 1/20 0.46
MET P08581 1/20 0.44
KDM5B Q9UGL1 1/20 0.43
HDAC4 P56524 1/20 0.42
METAP2 P50579 1/20 0.41
POLQ O75417 1/20 0.40
CYP2A6 P11509 1/20 0.39
ALDH1A1 P00352 3/20 0.39
HTT P42858 1/20 0.39
RECQL P46063 1/20 0.39
KDM4E B2RXH2 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15345191 0.90 CCR1 (0.47) CYP11B1CYP11B2NOTUMCCR1CCR5
SCHEMBL15341897 0.85 CYP11B1 (0.53) CYP11B1CYP11B2NOTUMGRM5MET
SCHEMBL15345169 0.80 GRM5 (0.50) CYP11B1CYP11B2CCR1CCR5CCR8
SCHEMBL15345180 0.80 CCR1 (0.41) CYP11B1CYP11B2NOTUMCCR1CCR5
SCHEMBL154510 0.79 CYP11B1 (0.52) CYP11B1CYP11B2NOTUMHDAC4ALDH1A1
SCHEMBL19905065 0.79 CYP11B1 (0.52) CYP11B1CYP11B2NOTUMGRM5MET
SCHEMBL15344951 0.76 CYP11B2 (0.59) CYP11B1CYP11B2CCR1CCR5CCR8
SCHEMBL15345163 0.76 WDR5 (0.53) CYP11B1CYP11B2NOTUMCCR1CCR5
SCHEMBL15341914 0.75 PFKFB3 (0.43) CYP11B1CYP11B2NOTUMGRM5MET
SCHEMBL30268281 0.75 KDM4E (0.59) CYP11B1CYP11B2NOTUMGRM5KDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3070081-B1 BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION GILEAD SCIENCES INC (US) 2018-02-28 EP disclosed
US-20160015690-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-01-21 US disclosed
US-8987250-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-03-24 US disclosed
US-20130281433-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015690-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 CYP11B1 20/4885CYP11B2 19/4885NOTUM 2211/4885
US-20130281433-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 CYP11B1 20/4885CYP11B2 19/4885NOTUM 2211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.